Overview

An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors

Status:
Completed
Trial end date:
2015-09-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the correlation between UGT1A1 genotypes and the safety of CPT-11 plus platinum analogues (cisplatin, carboplatin and nedaplatin) regimens for patients with lung cancer, cervical cancer, ovarian cancer and gastric cancer.
Details
Lead Sponsor:
Daiichi Sankyo Co., Ltd.
Treatments:
Carboplatin
Cisplatin
Irinotecan
Nedaplatin